BCIQ Profiles

Company Profile Report
0914 Astellas patient death
BioCentury & Getty Images

Product Development

What the latest patient death means for gene therapy development

Dosing, pre-existing liver pathology and vector-specific effects all possible contributors to fourth death in Astellas trial

Liver toxicity concerns mount for gene therapies, as dosing, pre-existing liver pathology and vector-specific effects all could have contributed to fourth death in Astellas trial.

Sep 15, 2021 | 12:33 AM GMT

The fourth death of a patient in Astellas’ gene therapy trial for X-linked myotubular myopathy is not likely to have the same broad derailing effect across gene

Read the full 886 word article

How to gain access

Continue reading with a
two-week free trial.